Nexstim Continues to Report Very Promising MDD Treatment Outcomes with Remission Rate Greater than 50%

Press Release, Helsinki, June 21, 2021 at 10:30 AM (EEST)

Nexstim Continues to Report Very Promising MDD Treatment Outcomes with Remission Rate Greater than 50%

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") reports very promising clinical outcomes of the 187 patients who have completed Nexstim SmartFocus® rTMS treatment with Nexstim NBT® system for major depressive disorder (MDD).

Treatment outcomes of these 187 patients were very good: 50.3% were in remission at end of treatment and 77.0 % had obtained a clinical response.

These outcomes are clearly higher than what is usually reported for MDD: In a well-conducted multisite study, remission rates were 26.5-28.7 % and the patient-reported response rates were 41.5-56.4 %¹. The patient-reported remission and response rates are also higher than those reported in a large >3800 patient series for patients completing clinical rTMS treatment (remission 29.7-36.2%, response 62.7-70.4%)².

The clinical outcomes of majority of the patients treated with SmartFocus® rTMS in the United States are being collected in a registry — the information is provided by participating clinical sites using Nexstim’s SmartFocus® technology.

According to the registry, average general impression of receiving the SmartFocus® rTMS treatment reported by the patients completed the treatment was very positive with a mean score of 9.25 on a scale from 0 to 10 (10= best possible).

Mikko Karvinen, CEO of Nexstim, said: “Since our latest update on the patient registry in March, we have been happy to notice even more promising results of the SmartFocus® rTMS treatments with our Nexstim NBT® System. I am very proud of the current remission rate being more than 50% and the progress in terms of the number of patients in the registry is desirable when it comes to our strategic objectives.”

^{1) Carpenter L. et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012 Jul;29(7):587-96. Epub 2012 Jun 11.
2) Sackheim, H. et al. Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation. Journal of Affective Disorders 277 (2020) 65–74.}

Further information is available on the website www.nexstim.com or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com

Attachment

• PRESS RELEASE_Patient Registry_21062021_Final